Reflection paper on statistical methodology for the ...
The comparison of empirical data from quality characteristics of drug products (Quality Attributes, QA) is of importance in many areas of drug development. One common objective of such comparative data analyses is to demonstrate that two drug products (or drug substances) stemming from two different
Download Reflection paper on statistical methodology for the ...
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Standard Guideline for the Collection and Depiction of ...
www.dot.ga.gov5.0 UTILITY QUALITY LEVEL ATTRIBUTES . 5.1 Quality Level D . 5.2 Quality Level C . 5.3 Quality Level B . 5.4 Quality Level A . 6.0 DELIVERABLES FORMATTING . 6.1 General . 6.2 Basic Deliverable . 6.3 Quality Level Attributes . 6.4 Utility Depiction Legend . 6.5 Examples of Mapping Deliverables . 7.0 RELATIVE COSTS AND BENEFITS OF QUALITY LEVELS
Suggested Attributes to Determine Performance Evaluation ...
employees.wpcarey.asu.eduSuggested Attributes to Determine Performance Evaluation Ratings. Below are attributes to consider when looking for behaviors that represent an overall rating and/or a rating for ... • Is respected for the quality of judgments made • Makes judgments on the basis of careful and deliberative process.
What is the Meaning of Quality?
mpra.ub.uni-muenchen.dequality can only be gained at higher cost, because quality reflects the quantity of desirable attributes that a product includes, and because attributes are believed to be costly to produce, quality goods will be more expensive (Garvin, 1984). However, Ishikawa and Lu (1985) argued